Upper Respiratory Tract

Leiber unable to prove that 0.45 g of Yestimun twice a day guarded against the common cold

EFSA rejects Leiber’s beta-glucan common cold health claim

By Oliver Nieburg

The European Food Safety Authority (EFSA) has rejected a 13.5 health claim linking Leiber’s beta glucan Yestimun to defence against the common cold, but the company is gearing up for another application after claiming the regulator has been inconsistent.

Yakult won't be making any claims about battling chest infections in the near future

Yakult: Health claim rejection doesn’t affect our claims

By Shane Starling

Japanese probiotics giant Yakult says the writing into law of its rejected EU health claim for upper respiratory tract infection (URTI) benefits won’t alter its core sell in European markets that remained, “stable”.


Follow us


View more


Featured Suppliers